Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2004

View Archived Issues

Prognosis and predictors for survival in Alzheimer's disease after initial diagnosis

Benefits of zinc supplementation in the treatment of attention deficit hyperactivity disorder

S-3304 reported to inhibit MMP activity in advanced cancer

Good safety and pharmacokinetic profile of AMD-070 in healthy volunteers

Long-term effects of everolimus on allograft vascularity after cardiac transplantation

Melatonin reported to delay allograft rejection in a cardiac transplant model

Chemokine receptor CCR7 implicated in transplant arteriosclerosis

PKC-412 improves retinal volume and visual acuity in DME patients

Rasagiline reported to delay functional decline in early PD

Alpha lipoic acid reported to inhibit MMP-9 in MS patients

Eszopiclone improves next day function of elderly patients with chronic insomnia

Promising topical ciclosporin prodrug against corneal graft rejection

Zonisamide induces resolution of RLS symptoms

Affimed presents anti-CD3 antibodies and their use in transplant rejection therapy

Aventis patent covers new quinoline-based antibacterial agents

Gruenenthal presents novel 5-HT reuptake inhibitors for pain, depression, etc.

Two series of HNE inhibitors and their use claimed by Bayer scientists

Boehringer Ingelheim patent covers MCH antagonists for obesity and other uses

New efflux pump inhibitors under investigation at Essential Therapeutics

Incara's catalytic antioxidant, AEOL-10150, prolongs survival in ALS mice

Biovitrum licenses project in metabolic diseases

CRADA covers evaluation of CEL-1000 with new adjuvants against malaria

Primary endpoints met in FluBlOk phase IIb trial

Cubist discontinues OCTX development program

OrthoLogic to acquire Chrysalis BioTechnology

Phase II TroVax trial cleared to commence for metastatic renal cancer

Polyphenon E Ointment enters phase II trial for actinic keratosis

Interim results for Theralux in NHL

ATI-7505 enters clinic

Jerini extends Baxter collaboration

Point's boroproline compound shows peptide adjuvant activity

SBIR supports development of gp41 inhibitors at Locus

Latest Rapinex NDA filing accepted for review